Nothing Special   »   [go: up one dir, main page]

UY33539A - ALK CHEMICAL COMPOUNDS - Google Patents

ALK CHEMICAL COMPOUNDS

Info

Publication number
UY33539A
UY33539A UY0001033539A UY33539A UY33539A UY 33539 A UY33539 A UY 33539A UY 0001033539 A UY0001033539 A UY 0001033539A UY 33539 A UY33539 A UY 33539A UY 33539 A UY33539 A UY 33539A
Authority
UY
Uruguay
Prior art keywords
alk
chemical compounds
formula
methods
compounds
Prior art date
Application number
UY0001033539A
Other languages
Spanish (es)
Inventor
Aquila Brian
Kamhi Victor
Peng Bo
Pontz Timothy
Jamal Carlos Saeh
Thakur Kumar
Yang Bin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY33539A publication Critical patent/UY33539A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
    • C07F9/65685—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine oxide or thioxide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de Fórmula (I) y/o Fórmula (Ia) y a sus sales, composiciones farmacéuticas, métodos de empleo y métodos para su preparación. Estos compuestos inhiben la actividad cinasa de ALK y, por lo tanto, se pueden utilizar para tratar el cáncer.The present invention relates to compounds of Formula (I) and / or Formula (Ia) and their salts, pharmaceutical compositions, methods of use and methods for their preparation. These compounds inhibit ALK kinase activity and, therefore, can be used to treat cancer.

UY0001033539A 2010-08-02 2011-08-01 ALK CHEMICAL COMPOUNDS UY33539A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36991710P 2010-08-02 2010-08-02
US37205510P 2010-08-09 2010-08-09
US39094410P 2010-10-07 2010-10-07

Publications (1)

Publication Number Publication Date
UY33539A true UY33539A (en) 2012-02-29

Family

ID=45527326

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033539A UY33539A (en) 2010-08-02 2011-08-01 ALK CHEMICAL COMPOUNDS

Country Status (14)

Country Link
US (1) US8461170B2 (en)
EP (1) EP2601186A2 (en)
JP (1) JP2013534221A (en)
KR (1) KR20130096241A (en)
CN (1) CN103153982A (en)
AR (1) AR089550A1 (en)
AU (1) AU2011287386A1 (en)
BR (1) BR112013002587A2 (en)
CA (1) CA2805827A1 (en)
MX (1) MX2013001361A (en)
RU (1) RU2013109132A (en)
TW (1) TW201219383A (en)
UY (1) UY33539A (en)
WO (1) WO2012017239A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037645T2 (en) 2011-07-27 2018-09-28 Astrazeneca Ab 2. (2,4,5-substituted-anilino) pyrimidine derivatives suitable for cancer treatment as EGFR modulators
CN102899882B (en) * 2012-11-07 2014-08-06 西南大学 Method for preparing super-hydrophilic polyester fabric with phosphoric acid
CN104876914B (en) * 2014-02-28 2017-04-19 山东轩竹医药科技有限公司 Pyrimidine derivative type anaplastic lymphoma kinase inhibitor
CN105085550B (en) * 2014-05-21 2017-05-24 海门慧聚药业有限公司 ALK kinases inhibitor and preparation method thereof
PH12016502453B1 (en) * 2014-06-19 2022-11-23 Takeda Pharmaceuticals Co Heteroaryl compounds for kinase inhibition
JP6854762B2 (en) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Inhibitor of cyclin-dependent kinase 7 (CDK7)
CA2978518C (en) 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
KR102051609B1 (en) * 2015-08-31 2019-12-03 우시 상량 바이오테크놀로지 씨오., 엘티디. 2-arylaminopyridine, pyrimidine or triazine derivatives and methods for their preparation and use
CN106810553B (en) * 2015-11-30 2020-03-17 江苏正大丰海制药有限公司 3- (4, 5-substituted aminopyrimidine) phenyl derivative and application thereof
AR110038A1 (en) 2016-05-26 2019-02-20 Kalyra Pharmaceuticals Inc EGFR INHIBITING COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT; METHODS TO IMPROVE OR TREAT A CANCER; METHOD FOR INHIBITING THE REPLICATION OF A WRONG GROWTH OR A TUMOR; METHODS TO INHIBIT THE ACTIVITY OF EGFR; AND USES OF COMPOUNDS
JP6608565B2 (en) * 2017-01-26 2019-11-20 ハンミ ファーマシューティカルズ カンパニー リミテッド Pyrimidine compounds and pharmaceutical uses thereof
WO2019019043A1 (en) * 2017-07-26 2019-01-31 鼎科医疗技术（苏州）有限公司 Surface liquefied drug coating balloon
KR102548191B1 (en) * 2018-04-09 2023-06-28 상하이테크 유니버시티 Targeted proteolytic compounds, their antitumor applications, their intermediates and applications of intermediates
US12187701B2 (en) 2018-06-25 2025-01-07 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
KR101954370B1 (en) * 2018-07-25 2019-03-05 한미약품 주식회사 Pyrimidine compounds and pharmaceutical composition for preventing or treating cancers comprising the same
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (en) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) A method of treating cancer that has acquired resistance to a kinase inhibitor
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN113387935B (en) * 2021-07-23 2022-06-10 苏州雅深智慧科技有限公司 Compound for inhibiting triple-mutation epidermal growth factor receptor tyrosine kinase and application thereof
CN116763792B (en) * 2023-06-19 2024-03-12 西安国际医学中心医院 Application of HG-14-10-04 in preparing medicament for treating esophageal squamous carcinoma
WO2025014773A1 (en) 2023-07-07 2025-01-16 Viridian Therapeutics, Inc. Methods of treating chronic thyroid eye disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ES2194181T3 (en) 1996-02-13 2003-11-16 Astrazeneca Ab DERIVATIVES OF QUINAZOLINE AS VEGF INHIBITORS.
ATE211134T1 (en) 1996-03-05 2002-01-15 4-ANILINOQUINAZOLINE DERIVATIVES
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
AU2001266233B2 (en) 2000-07-07 2006-06-29 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
CA2633563A1 (en) 2005-12-23 2007-06-28 Astrazeneca Ab Antibacterial pyrrolopyridines, pyrrolopyrimidines, and pyrroloazepines
JP2009541318A (en) * 2006-06-22 2009-11-26 メルク エンド カムパニー インコーポレーテッド Tyrosine kinase inhibitor
WO2008150799A1 (en) * 2007-06-01 2008-12-11 Smithkline Beecham Corporation Imidazopyridine kinase inhibitors
EA201000341A1 (en) * 2007-08-23 2010-10-29 Астразенека Аб 2-ANILINOPURIN-8-ONE AS TTK / MPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
TW201022262A (en) 2008-10-29 2010-06-16 Astrazeneca Ab Novel compounds 515

Also Published As

Publication number Publication date
CN103153982A (en) 2013-06-12
EP2601186A2 (en) 2013-06-12
CA2805827A1 (en) 2012-02-09
RU2013109132A (en) 2014-09-10
US20120028924A1 (en) 2012-02-02
WO2012017239A3 (en) 2012-04-05
KR20130096241A (en) 2013-08-29
AR089550A1 (en) 2014-09-03
US8461170B2 (en) 2013-06-11
JP2013534221A (en) 2013-09-02
WO2012017239A2 (en) 2012-02-09
MX2013001361A (en) 2013-05-17
TW201219383A (en) 2012-05-16
AU2011287386A1 (en) 2013-03-07
BR112013002587A2 (en) 2019-09-24

Similar Documents

Publication Publication Date Title
UY33539A (en) ALK CHEMICAL COMPOUNDS
UY33547A (en) CHEMICAL COMPOUNDS Bcl-2 and Bcl-XL
NI201500167A (en) CHEMICAL COMPOUNDS
UY33440A (en) ? PYRIMIDINYL COMPOUNDS FOR USE AS ATR INHIBITORS ?.
BR112014030743A2 (en) neprilysin inhibitors
ECSP12012318A (en) PIRAZOLIL QUINAZOLINA CINASA INHIBITORS
EA201590224A1 (en) IMIDAZOTRIASINCARBONITRILE USED AS KINASE INHIBITORS
CR20120659A (en) PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR CANCER TREATMENT
UY35683A (en) POLYMORPH OF INHIBITORS OF TIROSINA KINASA OF BAZO (SYK)
PH12015500689A1 (en) Azaquinazoline inhibitors of atypical protein kinase c
CR20150371A (en) PRMT5 INHIBITORS AND THEIR USES
MD20150043A2 (en) Inhibitors of histone demethylases
BR112015003859A8 (en) Pyrazolopyrimidine compounds as kinase inhibitors
DOP2014000062A (en) BENZILINDAZOLS REPLACED FOR USE AS INHIBITORS OF QUINASA BUB1 IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
UY32096A (en) DERIVATIVES OF 2-CARBOXAMIDE - CICLOAMINO - UREA SPECIFIC, ITS PHARMACUTICALLY ACCEPTABLE SALTS, COMPOSITIONS CONTAINING THEM, PRO-PHARMACES OF THE SAME, PROCESSES FOR PRODUCTION AND APPLICATIONS
BR112012024822B8 (en) Compound, use of a compound and pharmaceutical composition
BR112013016595A2 (en) neprilysin inhibitors
BR112014000792A2 (en) Piperidinyl Compounds for Use as Tanquirase Inhibitors
DOP2015000170A (en) CHEMICAL COMPOUNDS
UY33238A (en) "Compounds as bradykinin-b1 antagonists"
UY33655A (en) CCR30 CO-CRYSTALS AND SALES OF INHIBITORS
CL2014002661A1 (en) Compounds derived from thienopyrimidine or its salts, as alk kinase inhibitors; its preparation process; pharmaceutical composition that includes them, useful for the treatment of cancer.
BR112012023836A2 (en) tricyclic compounds and pbk inhibitors containing the same
BR112012024586A2 (en) purine compounds
CY1117565T1 (en) CONNECTED BICYCLE 2,4-DIAMINOPYRIDINE PRODUCER AS DOUBLE ALK AND FAK

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200813